Billions in write-downs: The Australian pharmaceutical company CSL thoroughly miscalculated with its Swiss subsidiary Vifor

The pharmaceutical company CSL must, 4 years after the $12 billion acquisition of its Swiss subsidiary Vifor Pharma, write off approximately one third of the purchase price. Disappointing business prospects and a lack of product success are leading to this multi-billion dollar write-down and job cuts.